Wall Street Zen Upgrades Synaptogenix (NASDAQ:TAOX) to “Hold”

Synaptogenix (NASDAQ:TAOX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Synaptogenix has a consensus rating of “Sell”.

Synaptogenix Price Performance

NASDAQ:TAOX opened at $6.40 on Friday. Synaptogenix has a 52 week low of $1.84 and a 52 week high of $11.98. The company has a fifty day simple moving average of $7.26. The stock has a market capitalization of $45.63 million, a P/E ratio of -0.32 and a beta of 1.93.

Synaptogenix (NASDAQ:TAOX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($1.56) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million during the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.